TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Genscript Biotech ( (HK:1548) ) has issued an announcement.
Genscript Biotech Corporation reported significant financial growth in its unaudited consolidated interim results for the first half of 2025. The company achieved an 81.9% increase in revenue from continuing operations, amounting to approximately US$518.8 million, and a 140.1% rise in gross profit to US$320.6 million. Despite a net loss of US$24.5 million, largely due to a US$193.7 million share of loss from Legend Group, the adjusted net profit surged by 509.6% to US$178.0 million. This financial performance highlights Genscript’s robust business operations and strategic positioning in the biotech industry, with positive implications for stakeholders as the company continues to enhance its market presence.
More about Genscript Biotech
Genscript Biotech Corporation is a biotechnology company incorporated in the Cayman Islands. It operates in the life sciences industry, focusing on providing a range of products and services including gene synthesis, peptide synthesis, protein production, and antibody development. The company is listed on the Hong Kong Stock Exchange and is known for its innovative solutions in the biotech sector.
YTD Price Performance: 80.08%
Average Trading Volume: 29,624,681
Technical Sentiment Signal: Buy
Current Market Cap: HK$38.45B
Find detailed analytics on 1548 stock on TipRanks’ Stock Analysis page.